Dr. Sunitha Vemulapalli
Claim this profileAultman Health Foundation
About Sunitha Vemulapalli
Education:
- Earned a Medical Degree (MD), with the specific institution not mentioned.
Experience:
- Specializes in breast cancer care at Aultman Health Foundation.
- Boasts over 20 years of experience in breast cancer patient care.
- Integral part of the multidisciplinary team at Aultman's Breast Care Center, recognized as a "Center of Excellence" by the American College of Radiology and fully accredited by the National Accreditation Program for Breast Centers.
Area of expertise
Breast Cancer
Sunitha Vemulapalli has run 10 trials for Breast Cancer. Some of their research focus areas include:
Lung Cancer
Sunitha Vemulapalli has run 7 trials for Lung Cancer. Some of their research focus areas include:
Affiliated Hospitals
Aultman Health Foundation
Aultman Alliance Community Hospital
Clinical Trials Sunitha Vemulapalli is currently running
Selumetinib + Olaparib
for Ovarian and Endometrial Cancer
This phase II ComboMATCH treatment trial compares selumetinib plus olaparib to selumetinib alone in women with endometrial or ovarian (fallopian tube and primary peritoneal) cancer that has come back (recurrent) or that remains despite treatment (persistent) and harbors a mutation in the RAS pathway. Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. The addition of olaparib to selumetinib could increase the percentage of tumors that shrink as well as lengthen the time that the tumors remain stable (without progression) as compared to selumetinib alone.
Recruiting
1 award
Phase 2
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting
2 awards
Phase 3
27 criteria
More about Sunitha Vemulapalli
Clinical Trial Related
6 years of experience running clinical trials · Led 25 trials as a Principal Investigator · 8 Active Clinical Trials
Treatments Sunitha Vemulapalli has experience with
- Paclitaxel
- Ipatasertib
- Binimetinib
- Fulvestrant
- Biospecimen Collection
- Pembrolizumab
Breakdown of trials Sunitha Vemulapalli has run
Breast Cancer
Lung Cancer
Breast cancer
Non-Small Cell Lung Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Sunitha Vemulapalli specialize in?
Sunitha Vemulapalli focuses on Breast Cancer and Lung Cancer. In particular, much of their work with Breast Cancer has involved HER2 positive patients, or patients who are ER positive.
Is Sunitha Vemulapalli currently recruiting for clinical trials?
Yes, Sunitha Vemulapalli is currently recruiting for 8 clinical trials in Canton Ohio. If you're interested in participating, you should apply.
Are there any treatments that Sunitha Vemulapalli has studied deeply?
Yes, Sunitha Vemulapalli has studied treatments such as Paclitaxel, Ipatasertib, Binimetinib.
What is the best way to schedule an appointment with Sunitha Vemulapalli?
Apply for one of the trials that Sunitha Vemulapalli is conducting.
What is the office address of Sunitha Vemulapalli?
The office of Sunitha Vemulapalli is located at: Aultman Health Foundation, Canton, Ohio 44710 United States. This is the address for their practice at the Aultman Health Foundation.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.